PMID- 37916370
OWN - NLM
STAT- MEDLINE
DCOM- 20231107
LR  - 20231107
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 27
IP  - 20
DP  - 2023 Oct
TI  - Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive 
      diagnosis of mesothelioma in effusion cytology.
PG  - 10001-10007
LID - 34180 [pii]
LID - 10.26355/eurrev_202310_34180 [doi]
AB  - OBJECTIVE: The cytological diagnosis of mesothelioma is a controversial issue, 
      and definitive diagnosis often requires ancillary tests. The aim of this study 
      was to investigate the contribution of BRCA1-associated protein (1) (BAP1) loss 
      and p16 (CDKN2A) homozygous deletion (HD) on the early diagnosis of mesothelioma 
      in effusion fluids. MATERIALS AND METHODS: Between 2019-2022, 21 pleural and 
      peritoneal fluid samples diagnosed with atypical mesothelial proliferation in our 
      institution were included in the study. The slides of the cases that underwent 
      BAP1 immunohistochemistry (IHC) were retrieved from the archive and re-examined. 
      Homozygous deletion (HD) of p16 (CDKN2A) was investigated by the fluorescence in 
      situ hybridization (FISH) method in cell blocks of cytology samples. At least 100 
      atypical mesothelial cells were counted in each case, and the HD threshold value 
      was >10%. RESULTS: The mean age of the cases was 63.47 years (34-90 years), 
      female/male ratio was 3/1. Of the pleural mesothelioma cases, 16 were 
      epithelioid, 2 were biphasic, and 1 were sarcomatoid. Two cases were diagnosed 
      with peritoneal well-differentiated papillary mesothelioma (WDPM). BAP1 loss was 
      observed in 11 (69%) of 16 cases. HD deletion of p16 (CDKN2A) was seen in 11 
      (58%) patients with FISH. The HD threshold value was 10-20% in 6 of the cases, 
      30-50% in 3 cases, and above 90% in 2 cases. While HD deletion was observed in 
      p16 (CDKN2A) in all biphasic and sarcomatoid cases (n=3), no deletion was 
      observed in peritoneal WDPM (n=2). Positivity was observed with at least one 
      method in 12 (86%) of 14 pleural mesotheliomas who underwent both BAP1 IHC and 
      p16 (CDKN2A) FISH. Due to technical reasons, the FISH signal could not be 
      obtained in two cell blocks, so no results could be obtained. CONCLUSIONS: 
      Asbestos exposure in areas where mesothelioma is endemic and/or the presence of 
      proliferating mesothelial cells in cytological examination are important clues 
      for diagnosis. In controversial cases, BAP1 IHC should be the first step in an 
      ancillary test. Although the FISH method applied to cell blocks has 
      cytology-specific limitations and difficulties, investigating the p16 (CDKN2A) 
      deletion with FISH in selected cases will contribute to the diagnosis.
FAU - Aydogdu, G
AU  - Aydogdu G
AD  - Department of Pathology, Faculty of Medicine, Dicle University Diyarbakir, 
      Turkey. gulay.aydogdu@balikesir.edu.tr.
FAU - Ozekinci, S
AU  - Ozekinci S
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (BAP1 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CDKN2A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor Proteins)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 3.4.19.12 (Ubiquitin Thiolesterase)
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Biomarkers, Tumor/analysis
MH  - Cyclin-Dependent Kinase Inhibitor p16/genetics
MH  - Cyclin-Dependent Kinase Inhibitor Proteins
MH  - Homozygote
MH  - In Situ Hybridization, Fluorescence
MH  - *Lung Neoplasms/genetics
MH  - *Mesothelioma/diagnosis/genetics/metabolism
MH  - *Mesothelioma, Malignant
MH  - *Pleural Neoplasms
MH  - Sequence Deletion
MH  - Tumor Suppressor Proteins/genetics/analysis
MH  - Ubiquitin Thiolesterase/genetics
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
EDAT- 2023/11/02 06:42
MHDA- 2023/11/03 06:43
CRDT- 2023/11/02 04:43
PHST- 2023/11/03 06:43 [medline]
PHST- 2023/11/02 06:42 [pubmed]
PHST- 2023/11/02 04:43 [entrez]
AID - 34180 [pii]
AID - 10.26355/eurrev_202310_34180 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2023 Oct;27(20):10001-10007. doi: 
      10.26355/eurrev_202310_34180.